Lba02-12 is learning curve important while performing psma-pet? analysis of detection rate according to gleason score and psa level in two timeframes at a brazilian high-volume center

You have accessJournal of UrologyCME1 Apr 2023LBA02-12 IS LEARNING CURVE IMPORTANT WHILE PERFORMING PSMA-PET? ANALYSIS OF DETECTION RATE ACCORDING TO GLEASON SCORE AND PSA LEVEL IN TWO TIMEFRAMES AT A BRAZILIAN HIGH-VOLUME CENTER Paulo Lages, Michelle Barbosa, Paulo Bergerot, Luciana Lages, Luciano Prado, Leonardo Prado, Pamela Muniz, Mariane Fontes, Marcella Prado, and Daniel Almeida Paulo LagesPaulo Lages More articles by this author , Michelle BarbosaMichelle Barbosa More articles by this author , Paulo BergerotPaulo Bergerot More articles by this author , Luciana LagesLuciana Lages More articles by this author , Luciano PradoLuciano Prado More articles by this author , Leonardo PradoLeonardo Prado More articles by this author , Pamela MunizPamela Muniz More articles by this author , Mariane FontesMariane Fontes More articles by this author , Marcella PradoMarcella Prado More articles by this author , and Daniel AlmeidaDaniel Almeida More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003361.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: PSMA PET/CT scan (68Ga-PSMA PET/CT) has emerged as a highly accurate method for assessing disease staging in patients with newly diagnosed localized high-risk prostate cancer and for recurrent disease. This has resulted in treatment plan modification in up to two-thirds of patients. PSMA PET/CT is commercially available in Brazil for a decade and growing experience with this test has led to more precise results over the years. METHODS: We retrospectively reviewed the results of PSMA PET/CT scans performed on patients at all disease stages in a single institution in Brasilia from 2015-2018 and 2021-2022. The results were correlated with available clinicopathological information in patients with recurrent disease in two separated timeframes. RESULTS: From 2015-2019, 351 exams were performed, with 303 in the setting of recurrent disease. From 2021-2022, 297 tests were executed with 283 in the recurrent disease setting. Clinicopathological information was available for 648 patients, with 586 patients in the setting of recurrent disease after first line treatment. CONCLUSIONS: There was a clinically relevant increase in the detection rate for patients with PSA ≤ 0.5 ng/mL and Gleason score ≤3+4, possibly as a result of the learning curve for this challenging scenario. However, we found a similar detection rate among other clinicopathological characteristics. Our data supports the need for ongoing training for the analysis of PSMA PET/CT results. Source of Funding: The authors © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1191 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Paulo Lages More articles by this author Michelle Barbosa More articles by this author Paulo Bergerot More articles by this author Luciana Lages More articles by this author Luciano Prado More articles by this author Leonardo Prado More articles by this author Pamela Muniz More articles by this author Mariane Fontes More articles by this author Marcella Prado More articles by this author Daniel Almeida More articles by this author Expand All Advertisement PDF downloadLoading ...